Hongene is thrilled to announce our participation in CSGCT. Cell and gene therapy (CGT) is redefining the boundaries of human disease treatment. As one of the most active countries in global CGT research and development pipelines, with abundant clinical resources and cutting-edge policy innovation, China is contributing the "China Solution" and "China Wisdom" to the global CGT development through its unique institutional advantages, scientific research strength, and industrial ecosystem, becoming an indispensable force in the global CGT innovation ecosystem.
On 19-20 September 2026, the China Cell and Gene Therapy Conference (CSGCT) will be held again at the Exhibition and Conference Centre in the Zhongguancun National Innovation Demonstration Zone in Beijing. As the most internationally influential event in the Asia-Pacific region for the field of cell and gene therapy, CSGCT collaborates closely with ASGCT (American Society of Gene & Cell Therapy), gathering top global regulatory agencies, scientists, innovative pharmaceutical companies, clinical experts, supply chain enterprises, large pharmaceutical firms, and investment institutions based on the top international resources in the CGT field. This year's conference will feature one main forum and 23 high-end sub-forums, welcoming 300 top domestic and international experts, 3,000 participants, and 500 investment institutions, providing the latest information on global CGT regulation and market access, clinical breakthroughs, scientific advancements, technology and applications, high-quality collaborative projects, as well as domestic and international investment and business development needs, thereby creating a platform for deep exchange and cooperation between the Chinese cell and gene therapy industry and the global industrial chain.
Welcome to visit us at site. Let’s discuss how Hongene’s high-quality nucleic acid products and end-to-end RNA medicines solution can help make your project successful.